Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 554-559

  Gilli, Simone Cristina Olenscki ^a,b   de Souza Medina, Samuel ^a,b   de Castro, Vagner ^a,b   Fernandes, Luís Gustavo Romani ^a,b   Saad, Sara Teresinha Olalla ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Instituto Nacional de Ciência e Tecnologia Bioanalítica INCT Bioanalítica   (Brazil)

Author keywords

Glycocalicin index; Myelodysplastic syndrome; PIFT; Platelet indices; Thrombocytopenia

Indexed keywords

BIOLOGICAL MARKER; GLYCOCALICIN; IMMUNOGLOBULIN G; THROMBOCYTE ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; IMMUNOFLUORESCENCE TEST; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUANTITATIVE DIAGNOSIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; THROMBOCYTOPENIA;

AGED; BLOOD PLATELETS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 84858751449     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.10.003     Document Type: Article

References (31)

1. Layton D.M., Mufti G.J. Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia. Blut 1986, 53:423-436.
2. Brada S., de Wolf J., Hendriks D., Esselink M., Ruiters M., Vellenga E. The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36- sorted bone marrow cells of myelodysplasia patients. Blood 1996, 88:505-510.
3. Brada S.J., de Wolf J.T., Hendriks D.W., Smit J.W., Vellenga E. CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation. Leukemia 1998, 12:882-886.
4. Hofmann W.K., Kalina U., Koschmieder S., Seipelt G., Hoelzer D., Ottmann O.G. Defective megakaryocytic development in myelodysplastic syndromes. Leukemia & lymphoma 2000, 38:13-19.
5. Mufti G.J., Figes A., Hamblin T.J., Oscier D.G., Copplestone J.A. Immunological abnormalities in myelodysplastic syndromes I. Serum immunoglobulins and autoantibodies. British Journal of Haematology 1986, 63:143-147.
6. van de Loosdrecht A.A., Vellenga E. Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis. Medical Oncology (Northwood, London, England) 2000, 17:16-21.
7. Lambertenghi-Deliliers G., Annaloro C., Oriani A., Soligo D. Myelodysplastic syndrome associated with bone marrow fibrosis. Leukemia & lymphoma 1992, 8:51-55.
8. Hall A.G., Proctor S.J., Saunders P.W. Increased platelet associated immunoglobulin in myelodysplastic syndromes. British Journal of Haematology 1987, 65:245-246.
9. Billstrom R., Johansson H., Johansson B., Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes-clinical and cytogenetic features. European Journal of Haematology 1995, 55:42-48.
10. von dem Borne A.E., Vos J.J., van der Lelie J., Bossers B., van Dalen C.M. Clinical significance of positive platelet immunofluorescence test in thrombocytopenia. British Journal of Haematology 1986, 64:767-776.
11. Hebbar M., Kaplan C., Caulier M.T., Wattel E., Morel P., Wetterwald M., et al. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. British Journal of Haematology 1996, 94:112-115.
12. von dem Borne A.E., Verheugt F.W., Oosterhof F., von Riesz E., de la Riviere A.B., Engelfriet C.P. A simple immunofluorescence test for the detection of platelet antibodies. British Journal of Haematology 1978, 39:195-207.
13. Illes I., Pfueller S.L., Hussein S., Chesterman C.N., Martin J.F. Platelets in idiopathic thrombocytopenic purpura are increased in size but are of normal density. British Journal of Haematology 1987, 67:173-176.
14. Rajantie J., Javela K., Joutsi-Korhonen L., Kekomaki R. Chronic thrombocytopenia of childhood: use of non-invasive methods in clinical evaluation. European Journal of Haematology 2004, 72:268-272.
15. Kaito K., Otsubo H., Usui N., Yoshida M., Tanno J., Kurihara E., et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. British Journal of Haematology 2005, 128:698-702.
16. Steinberg M.H., Kelton J.G., Coller B.S. Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. The New England Journal of Medicine 1987, 317:1037-1042.
17. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
18. Houwerzijl E.J., Blom N.R., van der Want J.J., Louwes H., Esselink M.T., Smit J.W., et al. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood 2005, 105:3472-3479.
19. Numbenjapon T., Mahapo N., Pornvipavee R., Sriswasdi C., Mongkonsritragoon W., Leelasiri A., et al. A prospective evaluation of normal mean platelet volume in discriminating hyperdestructive thrombocytopenia from hypoproductive thrombocytopenia. International Journal of Laboratory Hematology 2008, 30:408-414.
20. Greiner J., Schmitt A., Giannopoulos K., Rojewski M.T., Gotz M., Funk I., et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010, 95:1191-1197.
21. Molldrem J.J., Lee P.P., Wang C., Champlin R.E., Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Research 1999, 59:2675-2681.
22. Cilloni D., Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematologica 2004, 112:79-84.
23. Bosch G.J., Joosten A.M., Kessler J.H., Melief C.J., Leeksma O.C. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996, 88:3522-3527.
24. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. British Journal of Haematology 1997, 99:699-705.
25. Wang J.D., Pan X.L., Yin Z., Sun J.H., Kong G.X., Chen Y.J., et al. Expression of specific antibodies against platelet glycoproteins in patients with mds and its significance. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui=Journal of Experimental Hematology/Chinese Association of Pathophysiology 2007, 15:95-98.
26. Hagenstrom H., Schlenke P., Hennig H., Kirchner H., Kluter H. Quantification of platelet-associated IgG for differential diagnosis of patients with thrombocytopenia. Thrombosis and Haemostasis 2000, 84:779-783.
27. Barsam S.J., Psaila B., Forestier M., Page L.K., Sloane P.A., Geyer J.T., et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011, 117:5723-5732.
28. Olsson B., Andersson P.O., Jernas M., Jacobsson S., Carlsson B., Carlsson L.M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Medicine 2003, 9:1123-1124.
29. Cines D.B., McKenzie S.E., Siegel D.L. Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura. Journal of Pediatric Hematology/Oncology 2003, 25(Suppl. 1):S52-S56.
30. Kuter D.J. New thrombopoietic growth factors. Blood 2007, 109:4607-4616.
31. Clarkson S.B., Bussel J.B., Kimberly R.P., Valinsky J.E., Nachman R.L., Unkeless J.C. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. The New England Journal of Medicine 1986, 314:1236-1239.